A panel of advisers to the FDA, several of them sellers of experimental peptides, will continue to consider on Friday whether to broaden access to poorly understood peptide treatments. Follow live updates.
View on Bluesky
Source: at://did:plc:kkf4naxqmweop7dv4l2iqqf5/app.bsky.feed.generator/news-2-0
Author: The New York Times (@nytimes.com)
View on Bluesky
Source: at://did:plc:kkf4naxqmweop7dv4l2iqqf5/app.bsky.feed.generator/news-2-0
Author: The New York Times (@nytimes.com)
